首页> PloS one> Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank.

Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank.

导出 OA

翻译打印收藏纠错

第一作者： Holly,Pavey

第一单位： Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom.

作者： Holly,Pavey ^[1] ; Spoorthy,Kulkarni ^[2] ; Angela,Wood ^[3] ; Yoav,Ben-Shlomo ^[4] ; Peter,Sever ^[5] ; Carmel,McEniery ^[1] ; Ian,Wilkinson ^[1]

作者单位： Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom. ^[1] Department of Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. ^[2] British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, United Kingdom.;Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, United Kingdom.;National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom.;The Alan Turing Institute, London, United Kingdom. ^[3] Population Health Sciences, University of Bristol, Bristol, United Kingdom. ^[4] National Heart and Lung Institute, Imperial College London, London, United Kingdom. ^[5]

医学主题词人类(Humans);抗高血压药(Antihypertensive Agents);生物标本库(Biological Specimen Banks);高血压(Hypertension);血管紧张素受体拮抗剂(Angiotensin Receptor Antagonists);回顾性研究(Retrospective Studies)

DOI 10.1371/journal.pone.0276781

PMID 36350810

发布时间 2025-05-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交